Boston Scientific Corp (BSX)vsNeuroone Medical Technologies Corp (NMTC)
BSX
Boston Scientific Corp
$48.55
-0.34%
HEALTHCARE · Cap: $70.87B
NMTC
Neuroone Medical Technologies Corp
$3.48
+0.29%
HEALTHCARE · Cap: $29.65M
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 161950% more annual revenue ($20.61B vs $12.72M). BSX leads profitability with a 17.3% profit margin vs -52.2%. BSX earns a higher WallStSmart Score of 76/100 (B+).
BSX
Strong Buy76
out of 100
Grade: B+
NMTC
Avoid27
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.4%
Fair Value
$37.35
Current Price
$48.55
$11.20 premium
Intrinsic value data unavailable for NMTC.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 100.0% YoY
Large-cap with strong market position
Growing faster than its price suggests
Reasonable price relative to book value
Strong operational efficiency at 20.6%
Revenue surging 72.5% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
No major concerns identified
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -123.6% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.
Bull Case : NMTC
The strongest argument for NMTC centers on Revenue Growth, Debt/Equity. Revenue growth of 72.5% demonstrates continued momentum.
Bear Case : BSX
No major red flags identified for BSX, but monitor valuation.
Bear Case : NMTC
The primary concerns for NMTC are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
BSX profiles as a mature stock while NMTC is a hypergrowth play — different risk/reward profiles.
BSX carries more volatility with a beta of 0.62 — expect wider price swings.
NMTC is growing revenue faster at 72.5% — sustainability is the question.
BSX generates stronger free cash flow (171M), providing more financial flexibility.
Bottom Line
BSX scores higher overall (76/100 vs 27/100), backed by strong 17.3% margins and 11.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Neuroone Medical Technologies Corp
HEALTHCARE · MEDICAL DEVICES · USA
NeuroOne Medical Technologies Corporation is a medical technology company. The company is headquartered in Eden Prairie, Minnesota.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?